Key Takeaways
- Shares of EYPT plummeted more than 71% to reach a 52-week low of $4.06 on August 17, 2026
- DURAVYU failed to achieve its primary visual acuity endpoint in the Phase 3 LUGANO trial’s complete patient population
- A supplementary ad hoc analysis demonstrated non-inferiority to aflibercept when excluding a small asymmetric patient group
- The trial’s secondary endpoints showed favorable results, with a 42% decrease in treatment frequency compared to aflibercept
- The company maintains its plan to submit a regulatory application in H1 2027, contingent on forthcoming LUCIA trial results
Shares of EyePoint Pharmaceuticals (EYPT) experienced a devastating collapse of over 71% on August 17, 2026, plummeting to a 52-week low of $4.06 following the release of topline data from the company’s critical Phase 3 LUGANO clinical study.
EyePoint Pharmaceuticals, Inc., EYPT
The study evaluated DURAVYU 2.7 mg as a treatment for wet age-related macular degeneration patients. Results revealed the investigational therapy did not achieve its pre-specified primary visual acuity endpoint in the complete patient population.
This unfavorable headline drove the immediate and severe market reaction.
The company attempted to provide additional perspective on the results. A post-hoc analysis that removed a small subset of patients experiencing vision deterioration unconnected to wet AMD demonstrated that DURAVYU achieved non-inferiority compared to on-label aflibercept. However, such retrospective analyses hold significantly less regulatory credibility than pre-determined primary endpoints, a reality that investors quickly acknowledged through the share price decline.
On a positive note, the secondary endpoints delivered encouraging outcomes. DURAVYU demonstrated a 42% reduction in treatment frequency versus aflibercept. Additionally, patients exhibited impressive supplement-free intervals extending through Week 56, maintained effective anatomic disease control, and the drug displayed a favorable safety profile with repeated administrations.
Parsing the Clinical Results
The therapeutic candidate didn’t experience complete failure. While it missed the pre-specified primary endpoint in the total patient populationāthe critical regulatory benchmarkāthe comprehensive data presents a more nuanced picture than the severe stock depreciation would indicate.
EyePoint now emphasizes its second pivotal Phase 3 study, LUCIA, with topline results anticipated in late 2026. The company still intends to pursue a U.S. regulatory submission during the first half of 2027, though this pathway now hinges substantially on the LUCIA trial outcomes.
The organization also maintains ongoing Phase 3 development programs targeting diabetic macular edema, sustaining pipeline momentum beyond the wet AMD indication.
Wall Street Price Targets Suggest Significant Upside
Prior to the trial data release, Mizuho had increased its price target for EYPT to $39 while reaffirming an Outperform rating. Stifel had launched coverage with a Buy recommendation and established a $40 price target.
The latest analyst rating on file shows a Buy recommendation with a $39 target price. This represents substantial potential appreciation from current trading levels, although these projections were established before today’s clinical data and likely face revision.
EYPT exhibits a beta of 1.74, underscoring the considerable volatility characteristic of this equity. Prior to today’s selloff, the stock had appreciated 33% over the preceding twelve-month period, illustrating the dramatic impact binary clinical catalysts exert on biotechnology valuations.
Shareholders recently voted to approve modifications to EyePoint’s 2023 Long-Term Incentive Plan, authorizing an additional 4.9 million shares. Board members including Gƶran Ando, M.D. and Jay S. Duker, M.D. secured election at the 2026 Annual Meeting for terms extending through 2027.
EyePoint’s market capitalization currently stands at roughly $1.27 billion. Management has indicated the company possesses sufficient cash resources to fund operations through Q4 2027.
Topline data from the LUCIA Phase 3 trial is anticipated in late 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
